---
layout: post
title: 'GPCR Structure: Muscarinic M2 receptor'
date: '2012-02-16T18:54:00.000Z'
author: John Overington
tags:
- GPCRs
modified_time: '2012-02-23T13:10:32.269Z'
thumbnail: http://3.bp.blogspot.com/-mkQOVI8wFCk/Tz1NktsP4EI/AAAAAAAABj0/IVpMKeD067Q/s72-c/gpcr_targets.png
blogger_id: tag:blogger.com,1999:blog-2546008714740235720.post-367506847104775769
blogger_orig_url: http://chembl.blogspot.com/2012/02/gpcr-structure-muscarinic-m2-receptor.html
---

<div class="separator" style="clear: both; text-align: center;">
<a href="http://3.bp.blogspot.com/-mkQOVI8wFCk/Tz1NktsP4EI/AAAAAAAABj0/IVpMKeD067Q/s1600/gpcr_targets.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="300" src="http://3.bp.blogspot.com/-mkQOVI8wFCk/Tz1NktsP4EI/AAAAAAAABj0/IVpMKeD067Q/s320/gpcr_targets.png" width="320" /></a></div>
<br />
<br />
Another GPCR structure this week in <a href="http://www.nature.com/">Nature</a>, this time, human muscarinic M2 receptor, complexed with an antagonist - <a href="http://en.wikipedia.org/wiki/3-Quinuclidinyl_benzilate">3-quinuclidinyl-benzilate</a>&nbsp;- a controlled military incapacitation agent (<a href="https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/CHEMBL12980">CHEMBL12980</a>); a link to the paper is <a href="http://www.nature.com/nature/journal/vaop/ncurrent/full/nature10753.html">here</a>. A key difference to previously known structures is the large channel-like binding site. Coordinates are here PDBe:<a href="http://www.ebi.ac.uk/pdbe-srv/view/entry/3uon/summary">3uon</a><br />
<br />
<style type="text/css">
<!--
FONT.bgMY1 {background: #99FF00 }
FONT.bgMY2 {background: #66FF00 }
FONT.bgMY3 {background: #33FF00 }
FONT.bgMY4 {background: #00FF66 }
FONT.bgMY5 {background: #00FFCC }
FONT.bgMY6 {background: #00CCFF }
FONT.bgMY7 {background: #0066FF }
FONT.bgMY8 {background: #0000FF }
FONT.bgMY9 {background: #6600FF }
FONT.bgMY10 {background: #CC00FF }
FONT.bgMY11 {background: #FF00CC }
FONT.bgMY12 {background: #FF0066 }
FONT.bgMY13 {background: #FF0000 }
FONT.bgMY14 {background: #FF3300 }
FONT.bgMY15 {background: #FF6600 }
FONT.bgMY16 {background: #FF9900 }
FONT.bgMY17 {background: #FFCC00 }
FONT.bgMY18 {background: #FFFF00 }
FONT.bgMY19 {background: #CCFF00 }
FONT.bgMY20 {background: #00FF00 }
-->
</style>

<br />
<pre>                          10        20        30        40        50  
3uon  (  20 )    tfe<span style="color: red;">vvfivlvag<u>s</u>l<u>S</u>lv<u>T</u>iig<u>N</u>ilVmv<u>S</u>Ikv</span><b>n</b><span style="color: maroon;">rhL</span><u>q</u><b>t</b><span style="color: red;">vn<u>n</u>yflfSLA<u>c</u>A<u>D</u></span>
                    aaaaaaaaaaaaaaaaaaaaaaaaaaaa 333  aaaaaaaaaaaaa

                          60        70        80        90        100 
3uon  (  70 )    <span style="color: red;">liiGv</span>f<span style="color: red;">SM<u>n</u>ly<u>t</u>l<b>y</b><u>t</u>v</span>i<i>g</i>y<u>W</u>pl<i>g</i><span style="color: red;">pvvÇ<u>d</u>lWlalDYvV<u>S</u>NA<u>s</u>Vm<u>N</u>Llii<u>S</u>f</span>
                 aaaaa aaaaaaaaaa       aaaaaaaaaaaaaaaaaaaaaaaaaaa

                          110       120       130       140       150 
3uon  ( 120 )    <span style="color: red;">dryf<u>c</u>v<u>t</u></span>kplty<span style="color: maroon;">pvk</span>r<b>t</b><span style="color: red;">tkmAgmmiaaAwvl<b><u>S</u></b>filwapaIlfw<u>q</u>fiv</span><i>g</i>v<u>r</u>
                 aaaaaaa     333  aaaaaaaaaaaaaaaaaaaaaaaaaaaaaa   

                          160       170       180       190       200 
3uon  ( 170 )    tVedg<b>e</b>Ç<u>y</u>I<span style="color: maroon;"><b><u>q</u></b></span><span style="color: maroon;">ff<u>s</u></span><b>n</b><span style="color: red;">aav<u>t</u>fg<u>t</u>Aiaa</span>F<span style="color: red;"><u>y</u></span><span style="color: red;">lpviiM<u>t</u>vlyw<u>h</u>isra<u>s</u></span>ksri p
                          3333 aaaaaaaaaaa aaaaaaaaaaaaaaaaaa      

                          210       220       230       240       250 
3uon  ( 378 )    pp<u><i>s</i></u>rek<span style="color: red;">kv<u>trt</u>ilaIllaFii<u>t</u>WapY<u>N</u>vmVlintf</span>çapçip<span style="color: red;">ntvw<u>t</u>iGyw</span>
                       aaaaaaaaaaaaaaaaaaaaaaaaaaaaa      aaaaaaaaa

                          260       270       
3uon  ( 428 )    <span style="color: red;">l<u>C</u>Yi</span><b><u>n</u></b><u>st</u><span style="color: red;">i<u>N</u>pa<u>c</u>Yal<u>c</u></span><b>n</b><span style="color: red;">atFkk<u>t</u>fk<u>h</u>l</span>lm
                 aaaa   aaaaaaaaa aaaaaaaaaa  

</pre>
<pre>A K. Haga
A A.C. Kruse
A H. Asada
A T. Yurugi-Kobayashi
A M. Shiroishi
A C. Zhang
A W.I. Weis
A T. Okada
A B.K. Kobilka
A T. Haga
A T. Kobayashi
%T Structure of the human M2 muscarinic acetylcholine receptor bound to an antagonist
%J Nature</pre>
<pre>%V 482</pre>
<pre>%P 547-551
%O http://dx.doi.org/10.1038/nature10753
%D 2012
</pre>
<br />
I only found the <a href="http://cmpd.scripps.edu/">GPCR Network website</a> today (doh!), there is a <a href="http://cmpd.scripps.edu/tracking_status.htm">great tracking chart</a> of ongoing structural programmes - so bring on the S1P and kappa opioid structures! (The picture above summarises their target selection)